The intended audience for this activity includes a wide range of health care professionals; many may deem this presentation beneficial.

Upon successful completion these educational sessions, participants should be better able to:

• List innovations in insulin therapy over the past 100 years and their impact on practice
• Recognize indications for initiation and/or advancement of insulin therapy for people with T2D
• Describe the range of insulin therapies and their potential benefits for individualizing treatment for people living with diabetes
• Discuss recent data on newer and emerging basal and prandial insulins, and insulin technology, and implications on treatment approaches for people living with diabetes

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

American Nurses Credentialing Center (ANCC)

Nurses/Nurse Practitioners
The Institute for Medical and Nursing Education, Inc. (IMNE) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC’s) Commission on Accreditation.

IMNE designates this educational activity for 1.5 contact hours of continuing education credit (0.15 CEUs). Accreditation by the ANCC’s Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Certified Diabetes Educators
ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through their participation in this activity.

Anne Peters, MD
Professor of Clinical Medicine
Keck School of Medicine
Director, University of Southern California
Los Angeles, CA

Vanita R. Aroda, MD
Director, Diabetes Clinical Research
Division of Endocrinology, Diabetes & Hypertension
Brigham and Women’s Hospital
Faculty, Harvard Medical School
Boston, MA

Wendy S. Lane, MD
Clinical Endocrinologist
Director of Clinical Research
Mountain Diabetes & Endocrine Center
Asheville, NC

Carol J. Levy, MD, CDCES
Associate Professor of Medicine, Department of Endocrinology, Diabetes and Bone Disease
Associate Professor, Department of Obstetrics, Gynecology and Reproductive Science
Director, Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research
Icahn School of Medicine at Mount Sinai
New York, NY

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The following faculty reported relevant financial relationships:
Anne Peters, MD: Advisory Board Member, Abbott Laboratories, Eli Lilly & Company, Lilly USA, LLC, Mannkind Corporation, Merck & Co., Novo Nordisk, Zealand Pharmaceuticals; Grant Recipient, Abbott Laboratories, Dexcom; Other, Teledoc, Omada Health
Vanita R. Aroda, MD: Consultant, Applied Therapeutics, Novo Nordisk, Pfizer, Inc., Sanofi;Spouse, employee Merck, Janssen Research & Development Company; Research Investigator, Applied Therapeutics, Eli Lilly & Company, Fractyl Laboratories, Novo Nordisk, Sanofi; Spouse, Stock Owner Merck, Janssen Research & Development Company.
Wendy S. Lane, MD: Advisory Board Member, Novo Nordisk; Consultant, Xeris Pharmaceuticals; Grant Recipient, Novo Nordisk; Research Investigator, Novo Nordisk; Speaker, Novo Nordisk, Xeris Pharmaceuticals, Dexcom
Carol J. Levy, MD, CDCES: Advisory Board Member, Dexcom, Eli Lilly & Company; Grant Recipient, Abbott Diabetes; Research Investigator, Insulet Corporation, Dexcom

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:  Beret Anne Casey, MD

The following SPC Committee members reported financial relationships:

• Andjela T. Drincic, MD: Advisory Board Member, Corcept
• Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
• Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
• Amy Rothberg, MD: Spouse, consultant of Merck
• Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:

Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The Endocrine Society and IMNE staff associated with the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc.